Heartflow, Inc. (HTFL) Financial Ratio Screen

NASDAQ Healthcare United States USD 4155M
RATIOS FAIL*
Automated financial screen · activity assessed separately
Heartflow, Inc. (HTFL) is potentially non-compliant in the automated ratio model. While the debt ratio of 6.1% is acceptable, the cash and interest-bearing securities ratio of 49.2% exceeds the 30% threshold. Heartflow, Inc. operates in the Healthcare sector.

Track HTFL screening changes

Get an email when this stock's published screening status or underlying ratios change.

MSCI new-inclusion financial-ratio snapshot

HTFL financial screening at a glance

RATIOS FAIL*Financial ratios shown separately from business review — not a fatwa
Debt ratio
6.1%
Pass vs 30%
Cash ratio
49.2%
Fail vs 30%
Receivables + cash
57.3%
Fail vs 30%
Impermissible income
3.1%
Pass vs 5%

Calculation date: 2026-08-31. Financial period used: December 2025. The ratios are automated proxies inspired by published methodologies; they are not official index determinations.

Independent method comparison

What the available screens say

How MSCI, FTSE and S&P-style screens differ
Request this stock review
MSCI-styleFinancial criteria not metAt least one available ratio exceeds its threshold
FTSE/Yasaar-styleFinancial criteria not metAt least one available ratio exceeds its threshold
S&P-style provisionalNot yet availableRequired denominator or financial data is incomplete
Business activityAssessment pendingFinancial results do not determine business permissibility
Complete screening result: not yet completeA complete result requires both supported financial criteria and adequate activity evidence. This site does not issue a fatwa or official index decision.
Financial periodDecember 2025Calculation date2026-08-31S&P-style historynot availableLast activity reviewnot yet reviewed

The request button opens your email application with a pre-filled message. HalalStockGuide receives no address or request unless you choose to send it.

Business activity evidence

Activity assessment in progress

The supplied classification (Health Information Services) is only a starting point. Revenue evidence is being assessed before any complete screening conclusion.

Revenue segments: Not yet checked against an SEC annual filing.

Profile description reviewed: HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient's heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart's arteries. The company provides Heartflow RoadMap Analysis that offers an intuitive anatomic visualization of the coronary arteries; Heartflow FFRCT Analysis, which calculates blood flow and pinpoints clinically; and Heartflow Plaque Analysis that provides a comprehensive assessment of coronary plaque, enabling optimized medical treatment strategies. Its platform provides insights on blood flow, stenosis, and plaque volume and composition by overcoming the limitations of traditional non-invasive imaging tests. HeartFlow, Inc. was formerly known as Cardiovascular Simulation, Inc. and changed its name to HeartFlow, Inc. in May 2009. The company was incorporated in 2007 and is headquartered in San Francisco, California.

Sources to verify: Secondary company profile and classification · Issuer website · SEC issuer filings

A sector label or company description can flag a risk but cannot establish a compliant-revenue percentage. Only sourced segment disclosures may support that calculation.

Published-ratio reproductions (not certifications)

The table shows implemented MSCI and FTSE/Yasaar-style asset-based models plus a provisional S&P-style leverage reconstruction where a complete 36-month denominator exists. These are independent calculations, not official index results or Shariah determinations. See formulas, sources and limitations.

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
MSCI 6.1%
/ 30%
49.2%
/ 30%
57.3%
/ 30%
3.15%
/ 5%
RATIOS FAIL*
FTSE 6.1%
/ 33%
49.2%
/ 33%
57.3%
/ 50%
3.15%
/ 5%
RATIOS FAIL*

Financial Highlights

EPS
$-3.15
P/B Ratio
14.8
EV/EBITDA
-56.3
EV: $4.0B
Revenue
$176M
Growth: 47.6%
Current Ratio
5.1

Profitability

Gross Margin 80.1%
Operating Margin -27.9%
Net Margin -55.8%
Return on Equity (ROE) -154.2%
Return on Assets (ROA) -18.1%

Cash Flow & Balance Sheet

Operating Cash Flow-$54M
Free Cash Flow-$59M
Total Debt$22M
Debt-to-Equity9.7
Current Ratio5.1
Total Assets$359M

Price & Trading

Last Close$48.10
50-Day MA$32.37
200-Day MA$29.46
Avg Volume1.8M
52-Week Range
$20.13
$51.19

Financial data provenance and verification

The displayed fields were imported from yfinance on 2026-08-31 for the financial period December 2025. This is a secondary data feed and can differ from amended or newly filed statements.

Verification rule: check debt, cash, receivables, revenue and interest income against the latest primary filing before relying on an automated ratio.

About Heartflow, Inc. (HTFL)

CEO
Mr. John C.M. Farquhar
Employees
843
Sector
Healthcare
Industry
Health Information Services
Country
United States
Exchange
NASDAQ
Market Cap (listing currency)
USD 4155M
Currency
USD

HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient's heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart's arteries. The company provides Heartflow RoadMap Analysis that offers an intuitive anatomic visualization of the coronary arteries; Heartflow FFRCT Analysis, which calculates blood flow and pinpoints clinically; and Heartflow Plaque Analysis that provides a comprehensive assessment of coronary plaque, enabling optimized medical treatment strategies. Its platform provides insights on blood flow, stenosis, and plaque volume and composition by overcoming the limitations of traditional non-invasive imaging tests. HeartFlow, Inc. was formerly known as Cardiovascular Simulation, Inc. and changed its name to HeartFlow, Inc. in May 2009. The company was incorporated in 2007 and is headquartered in San Francisco, California.

Popular halal stock checks

Explore other frequently viewed automated stock screens and compare the available financial ratios.

Frequently Asked Questions

Is Heartflow, Inc. (HTFL) halal to invest in?

The current automated result is Financial criteria not met or an activity exclusion was detected. It uses available public financial fields and simplified methodology proxies. It is not a fatwa or an official determination by AAOIFI, DJIM, MSCI, S&P, or FTSE.

What is Heartflow, Inc.'s debt ratio?

Heartflow, Inc.'s debt ratio is 6.1% in the MSCI new-inclusion reproduction: total debt divided by total assets, against a 30% threshold. See the methodology page for the official source and limitations.

What are Heartflow, Inc.'s key financial metrics?

Heartflow, Inc. has a market capitalization of USD 4155M in its listing currency, and revenue of $176M. The company maintains a gross margin of 80.1% and a net margin of -55.8%. Return on equity stands at -154.2%.

How often is the screening data updated?

Calculation date: 2026-08-31. Financial period: December 2025. These dates are shown separately because regenerating this page does not refresh the underlying data.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.